Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Amgen today announced that the Company will discuss the data supporting the Repatha (evolocumab) Biologics License Application (BLA) for the treatment of high cholesterol with the U.S. Food and Drug Administration's (FDA) Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC).

10 Jun 2015

Study highlights the need to reduce non-communicable diseases

There is a great need to slow down the increasing number of people who die prematurely because of non-communicable diseases (NCDs) such as cardiovascular disease, diabetes and cancer.

10 Jun 2015

Study highlights the importance of nutrition for maintaining mental health

An international study involving the Faculty of Medicine and Dentistry of the University of Valencia, recently published in 'The Lancet Psychiatry', highlights the importance of nutrition for maintaining mental health. Lecturer of Psychiatry Vicent Balanzá has participated in this study.

10 Jun 2015

Reactions to stress may play key role in long-term health

Reacting positively to stressful situations may play a key role in long-term health, according to researchers.

10 Jun 2015

Detecting blood clots with a portable device

Blockages in lung arteries could be diagnosed safely in real-time helping as many as 20,000 respiratory patients in Australia each year with emerging technology being developed by electrical engineering researchers at the University of Sydney.

10 Jun 2015

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Sanofi and Regeneron Pharmaceuticals, Inc. today announced that the Endocrinologic and Metabolic Drugs Advisory Committee of the U.S. Food and Drug Administration recommended the approval of the investigational therapy Praluent (alirocumab) Injection.

9 Jun 2015

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

A clinical trial of the glucose-control drug sitagliptin among patients with type 2 diabetes and established cardiovascular disease has found it did not raise the risk of major adverse cardiovascular events.

9 Jun 2015

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

DalCor Pharmaceuticals and the Montreal Heart Institute announced today a collaboration in principle to conduct an international Phase III clinical trial which could result in a major clinical advance in cardiovascular personalised medicine.

8 Jun 2015

Daily sugar-sweetened beverage habit may increase NAFLD risk

A daily sugar-sweetened beverage habit may increase the risk for non-alcoholic fatty liver disease (NAFLD), researchers from the Jean Mayer USDA Human Nutrition Research Center on Aging (USDA HRNCA) at Tufts University report today in the Journal of Hepatology.

8 Jun 2015

Griffith student finds success in medical tourism

The world of medical tourism was not one that Dan Donner had ever considered as a potential career path, but today he can be found dividing his time between study at Griffith University and running a flourishing business in Thailand.

5 Jun 2015

Pivotal Therapeutics enrolls first patient in POMEGA Phase IIa clinical trial of PVT-100

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced today the enrollment of the first patient in Pivotal's POMEGA Phase IIa clinical trial with PVT-100.

4 Jun 2015

SCIEX and Metabolon® Launch the Lipidyzer™ Platform for Complete Lipid Analysis, from Sample to Biology

The new Lipidyzer™ Platform enables you to rapidly and accurately differentiate and quantitate over a thousand lipid species, and translates your data into knowledge with ease and efficiency.

4 Jun 2015

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Blood clots often form when lipid-rich plaques on the inner surface of arteries rupture and platelets aggregate at the site of injury. Cardiologists from Ludwig-Maximilians-Universitaet in Munich have now compared the effects of two new platelet aggregation inhibitors.

4 Jun 2015

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Researched and written by RAND Europe, with contributions from a panel of leading European medical, patient group and health economic experts, the Future of Anticoagulation Report explores how decisions made today can change and reshape the landscape of tomorrow...

3 Jun 2015

Childhood trauma increases vulnerability to different health problems in later life

Long-term changes in immune function caused by childhood trauma could explain increased vulnerability to a range of health problems in later life, according to new research by the Institute of Psychiatry, Psychology & Neuroscience at King's College London and the NIHR Maudsley BRC.

3 Jun 2015

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Novartis today announced new data from two Phase II studies of Zykadia (ceritinib), as well as one Phase II study of Tafinlar® (dabrafenib) in combination with Mekinist (trametinib) in certain patients with non-small cell lung cancer.

2 Jun 2015

Substantial pharmacogenetic information available on cardiovascular drugs

There is a wealth of published information describing interactions between drugs used to treat cardiovascular disease and the genetic variations that can affect how patients respond to them. But few heart specialists make routine use of this potentially life-saving data.

2 Jun 2015

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Novartis is highlighting data from an ongoing Phase II clinical study of CTL019, an investigational chimeric antigen receptor (CAR) T cell therapy, that indicate its potential in the treatment of specific types of hard-to-treat non-Hodgkin lymphoma.

2 Jun 2015

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Pivotal Therapeutics Inc., a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the three months ended March 31, 2015.

2 Jun 2015

Key lifestyle changes could help reduce risk of cognitive decline

The evidence is mounting: People can reduce their risk of cognitive decline by making key lifestyle changes. That is the conclusion of a new research summary published online today in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.

1 Jun 2015

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Amgen to discuss data supporting Repatha BLA for high cholesterol treatment with FDA EMDAC

Study highlights the need to reduce non-communicable diseases

Study highlights the importance of nutrition for maintaining mental health

Reactions to stress may play key role in long-term health

Detecting blood clots with a portable device

FDA's Advisory Committee recommends approval of Praluent (alirocumab) Injection

Glucose-control drug sitagliptin does not raise risk of cardiovascular events

DalCor, MHI partner to conduct Phase III clinical trial of investigational cardiovascular drug

Daily sugar-sweetened beverage habit may increase NAFLD risk

Griffith student finds success in medical tourism

Pivotal Therapeutics enrolls first patient in POMEGA Phase IIa clinical trial of PVT-100

SCIEX and Metabolon® Launch the Lipidyzer™ Platform for Complete Lipid Analysis, from Sample to Biology

LMU cardiologists study new approach to inhibit atherosclerotic plaque-induced platelet activation

Expert report highlights urgent action needed to lessen the future impact of Atrial Fibrillation in Europe

Childhood trauma increases vulnerability to different health problems in later life

ASCO 2015: Novartis presents data on Zykadia and Tafinlar studies for non-small cell lung cancer

Substantial pharmacogenetic information available on cardiovascular drugs

Novartis CTL019 CAR T cell therapy demonstrates potential to treat B-cell lymphomas

Pivotal Therapeutics reports net loss of $1.2 million for first quarter 2015

Key lifestyle changes could help reduce risk of cognitive decline

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cardiovascular Disease News and Research

Latest Cardiovascular Disease News and Research

Event guide: 4th Extra-Hepatic Lipid-Based Nanoparticles Delivery Summit eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in